What is Delstrigo
Tenofovir disoproxilThe Generic name of this drug
Treatment SummaryTenofovir disoproxil fumarate, sold under the brand name Viread, is a medication used to treat HIV and hepatitis B. It belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), and is meant to be taken in combination with other medications. Tenofovir disoproxil was approved by the FDA in 2001.
Vireadis the brand name
Delstrigo Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Viread
Tenofovir disoproxil
2001
149
Effectiveness
How Delstrigo Affects PatientsTenofovir is used to treat HIV-1 and Hepatitis B infections by preventing the virus from making copies of itself. Laboratory tests have shown that it is effective against HIV-1 at concentrations between 0.04 μM to 8.5 μM. Tenofovir has been found to work well in combination with other drugs used to treat HIV-1, such as nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors, as well as protease inhibitors. Clinical studies have also confirmed that it can effectively fight HIV-1 in cell cultures.
How Delstrigo works in the bodyTenofovir is an antiretroviral medicine used to reduce the amount of HIV in the body. It works by blocking a special enzyme that HIV needs to reproduce. When this enzyme is blocked, the virus can't make as many copies of itself. Tenofovir is absorbed and converted to its active form which is a type of chemical called a nucleotide analog. This chemical then binds to the HIV enzyme and stops it from working. It also prevents the virus from making DNA. In some cases, HIV can become resistant to tenofovir, meaning that it is not as effective at stopping the virus from reproducing
When to interrupt dosage
The suggested dosage of Delstrigo is based on the identified affliction, including Anti-Retroviral Agents, High Risk Patients and Chronic Hepatitis B. The measure of dosage fluctuates, depending on the procedure of delivery (e.g. Tablet or Tablet, film coated) provided in the table below.Condition
Dosage
Administration
Anti-Retroviral Agents
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
High Risk Patients
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
Chronic Hepatitis B Infection
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
Treatment Failure
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
adult and pediatric patients weighing at least 40 kg
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
HIV
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
Therapeutic procedure
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
Safer sex practices
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
Treatment Naive
245.0 mg, 300.0 mg, , 150.0 mg, 200.0 mg, 250.0 mg, 0.04 mg/mg, 0.033 mg/mg, 123.0 mg, 163.0 mg, 204.0 mg
Tablet, Tablet, film coated, Oral, , Tablet, film coated - Oral, Powder - Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Granule, Granule - Oral, Powder
Warnings
There are 20 known major drug interactions with Delstrigo.Common Delstrigo Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Tenofovir disoproxil is combined with Neomycin.
Tenofovir
Major
Tenofovir disoproxil may increase the nephrotoxic activities of Tenofovir.
Abacavir
Minor
Tenofovir disoproxil may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Tenofovir disoproxil may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Aclidinium
Minor
Tenofovir disoproxil may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Delstrigo Toxicity & Overdose RiskWhen it comes to breastfeeding, the Centers for Disease Control and Prevention recommend that mothers with HIV-1 not breastfeed their infants to prevent transmission. Mothers should not breastfeed if they are taking tenofovir disoproxil. There have been no studies done on pregnant women taking tenofovir disoproxil, but studies done on rats and rabbits showed no signs of harm to the fetus at doses up to 14 and 19 times the recommended human dose. To monitor the effects of this drug on pregnant women, a registry has been created for healthcare providers to register patients. Tenofov
Delstrigo Novel Uses: Which Conditions Have a Clinical Trial Featuring Delstrigo?
Currently, 46 active clinical trials are assessing the potential of Delstrigo to replace a current antiretroviral treatment regimen for certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable regimen at the start of therapy, as well as in treating Chronic Hepatitis B and HIV (Human Immunodeficiency Virus).Condition
Clinical Trials
Trial Phases
certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen
0 Actively Recruiting
Chronic Hepatitis B Infection
5 Actively Recruiting
Phase 3, Phase 2
HIV
50 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1
Treatment Naive
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting
Treatment Failure
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
adult and pediatric patients weighing at least 40 kg
0 Actively Recruiting
Safer sex practices
0 Actively Recruiting
High Risk Patients
0 Actively Recruiting
Delstrigo Reviews: What are patients saying about Delstrigo?
2Patient Review
6/25/2021 I gained weight when I switched to delstrigo, and my hiv 1rna levels increased.
Patient Q&A Section about delstrigo
What are the side effects of Delstrigo?
"The most common side effects of Delstrigo include abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever." - Anonymous Online Contributor
Unverified Answer
What does Delstrigo do?
"The DELSTRIGO prescription medication is used to treat HIV-1 infection in adults who have not received HIV-1 medicines in the past, or to replace their current HIV-1 medicines. This decision is made by the patient's healthcare provider after determining that the patient meets certain requirements." - Anonymous Online Contributor
Unverified Answer
Who manufactures Delstrigo?
"The European Commission red lighted Merck's DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO (doravirine), an NNRTI, both for the treatment of HIV-1 in [the European Union]." - Anonymous Online Contributor
Unverified Answer
How good is Delstrigo?
"In a study of 728 adults, 84% of those treated with Delstrigo had undetectable HIV levels in their blood (fewer than 40 copies/ml) after 48 weeks, compared to 80% of those given a combination of efavirenz, emtricitabine, and tenofovir disoproxil." - Anonymous Online Contributor
Unverified Answer